1. Text: | Print|

      GSK probe indicates tightened drug sector supervision

      2013-07-19 08:39 Xinhua Web Editor: Mo Hong'e
      1

      An ongoing probe into suspected economic violations by multinational drugmaker GlaxoSmithKline (GSK) employees is being seen as part of efforts to tighten supervision in the medical sector.

      The Ministry of Public Security announced last week that some employees from GSK China are being investigated for suspected bribery and tax-related violations. Four senior executives from the company are being held by police over their alleged involvement.

      The probe has shed light on instances of hidden bribery that have driven up medicine prices. However, the case is not the first of its kind to be uncovered in China.

      In December last year, the U.S. Securities and Exchange Commission (SEC) charged Eli Lilly and Company for its involvement in instances of alleged bribery that occurred in several countries, including China.

      Four months before the Eli Lilly case, Pfizer's subsidiary in China was also found to have been involved in bribery.

      The GSK suspects are believed to have several methods of concealment, such as channelling bribes through travel agencies.

      It is believed that the exposure of the bribery represents just the tip of the iceberg.

      An anonymous medical salesman from north China's Tianjin Municipality said salesmen have had to come up with more creative ways to bribe doctors and convince them to raise the cost of their medicine.

      "In most cases, the doctors don't extort money in such explicit terms, but it is certain that they will not order products from those who do not give them a 'good return'," he said.

      The unfair market advantage that enterprises have gained by using bribery may make it harder for smaller companies to survive and develop. In addition, the costs of bribery are eventually transferred to patients.

      According to suspect Liang Hong, a medication that costs only 30 yuan to produce could end up setting patients back 300 yuan due to bribery.

      Bribery can also affect patients' health, as bribes may influence doctors' decisions regarding what medication to prescribe.

      A commerce official said Wednesday that the GSK probe is part of efforts to improve China's business climate and create equal competition opportunities for domestic and overseas investors.

      The official said China firmly opposes any form of commercial bribery, and all companies, Chinese and foreign alike, will be subject to legal sanctions and assume legal responsibility if they break Chinese law.

      Comments (0)
      Most popular in 24h
        Archived Content
      Media partners:

      Copyright ©1999-2018 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.

      主站蜘蛛池模板: 亚洲精品国产精品乱码视色| 无码久久精品国产亚洲Av影片| 亚洲av无码精品网站| 亚洲乱码中文字幕小综合| 国产精品久久久久久亚洲小说| 国产一区二区三区免费| 成视频年人黄网站免费视频| 亚洲国产成人精品无码久久久久久综合 | 在线视频免费观看高清| 中文字幕亚洲一区二区三区 | 亚洲av极品无码专区在线观看| 美女黄色毛片免费看| 91精品免费观看| 免费在线观看a级毛片| 亚洲欧洲精品在线| 一个人看的免费视频www在线高清动漫| 久久国产高潮流白浆免费观看| 亚洲 国产 图片| 亚洲人成网网址在线看| 三级网站免费观看| 国产美女无遮挡免费视频网站| 亚洲av鲁丝一区二区三区| 特级aaaaaaaaa毛片免费视频| 免费专区丝袜脚调教视频| 美腿丝袜亚洲综合| 亚洲精品V天堂中文字幕| 日日麻批免费40分钟无码| 免费一级毛片一级毛片aa| 精品亚洲AV无码一区二区 | 久久成人18免费网站| 日韩在线天堂免费观看| 亚洲狠狠久久综合一区77777| 四虎永久在线精品免费一区二区 | 亚洲AV无码久久| jizz18免费视频| 午夜一级毛片免费视频| 亚洲视频免费在线观看| aa级女人大片喷水视频免费| 免费国产在线观看老王影院| 亚洲va精品中文字幕| 久久久精品午夜免费不卡|